No lethal dose identified at doses up to 20 mg/kg in animal studies No organ toxicity observed across multiple organ systems Negative mutagenicity testing across standard assays No teratogenic effects in pregnancy studies Limited long-term human data beyond 6 weeks Theoretical Considerations The primary theoretical concern relates to BPC-157s angiogenic properties
This systemic anti-inflammatory effect is one reason why researchers often report improvements in seemingly unrelated symptoms when using the peptide for a specific indication, experiencing reduced joint pain while treating a gut issue, for example, or improved recovery times while treating a specific injury
The label starts at 2.5 mg weekly, long-duration obesity evidence starts at 5 mg, and registered human activity has been measured as low as 1 mg in an early diabetes study. Each number answers a different question
Examines nitric oxide signaling, endothelial protection, and oxidative stress markers
Supply Patterns The heatmap above shows OOS rate per peptide per ISO week